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Calcineurin Activity and Inhibition in Skin and
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NPM Smit1, HH Van Rossum1, FP Romijn1, KJ Sellar1, M Breetveld2, S Gibbs2 and J Van Pelt1
Calcineurin (Cn) is the target of the immunosuppressive drugs cyclosporine A (CsA), tacrolimus (Trl), and
pimecrolimus (Prl). Trl and Prl are often used topically for treatment of various skin diseases. The Cn inhibitors
CsA and Trl are mostly used for maintenance therapy of transplant patients. Their long-term use, however,
causes a dramatic increase in skin cancer risk. By using a newly developed assay for Cn measurement in blood,
we were able to demonstrate Cn activity in total skin homogenates. A significantly higher activity was found in
epidermis compared to dermis. In skin cell cultures, fibroblasts showed the highest activity as compared to
keratinocytes and melanocytes. Of the Cn inhibitors, Trl showed stronger inhibition than CsA and Prl (57 and
55% in fibroblast and keratinocyte cultures, respectively). Also, the lowest IC50 (the half maximal inhibitory
concentration) values were found for Trl (0.5 and 1.3 nM in two different fibroblast cultures). Cn activity and its
inhibition can thus be studied in dermatological samples. The effects of Cn inhibition in fibroblasts and
keratinocytes may be of influence on the overall functioning of the skin immune system.
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INTRODUCTION
The enzyme calcineurin (Cn) plays a key role in the immune
response. In T cells, it is responsible for the dephosphoryla-
tion of the NFAT (nuclear factor of activated T cells), and its
subsequent nuclear translocation ultimately results in T-cell
activation (Winslow et al., 2003). In organ transplantation
patients, Cn is the main target for immunosuppression by the
Cn inhibitors cyclosporine A (CsA) and tacrolimus (Trl).
Besides its role in T cells, Cn plays a role in various tissues
and also in the skin (Reynolds and Al Daraji, 2002; Aramburu
et al., 2004). Al Daraji et al. (2002) have shown that in
keratinocytes, the nuclear translocation of NFAT is regulated
by Cn and influenced by Cn inhibitors. Furthermore, a role
for Cn in the differentiation of keratinocytes has been
described (Santini et al., 2001). Cn activity has been
demonstrated before in cultured lung fibroblasts with an
assay using 32P-radiolabeled substrate and the activity could
be inhibited by CsA (Chen et al., 2003). A role for Cn in
melanocytes is suggested, as CsA was shown to decrease
pigmentation in cultured human melanocytes, and Cn
inhibitors are used topically for treatment of vitiligo (Lee
and Kang, 2003; Taieb, 2005). The Cn inhibitors CsA, Trl,
and pimecrolimus (Prl) are also used for the treatment of other
dermatological diseases, such as psoriasis and atopic eczema
(Griffiths, 2001; Reynolds and Al Daraji, 2002).
For a long time, the treatment of organ transplant patients
with Cn inhibitors has been known to result in an increased
incidence of non-melanoma skin cancer (Hartevelt et al.,
1990), and nowadays the occurrence of various other types of
post-transplant malignancies are becoming an important
cause of mortality (Buell et al., 2005).
The studies mentioned above indicate a role for Cn in skin.
However, so far no direct measurement of Cn activity in skin
tissue or skin cells has been described. Recently, we
developed a new sensitive assay for spectrophotometric
measurement of Cn in leukocytes (Sellar et al., 2006). The
increased use and topical application of Cn inhibitors in
dermatological practice and the strong elevation of non-
melanoma skin cancer in transplant patients treated with Cn
inhibitors was the rationale to use this assay for our study on
Cn activity in the skin and the cells, which are the main
constituents of the dermis and epidermis.
RESULTS
In this study, the Cn assay was used to study Cn activity
in skin tissue and cultured cells derived from the skin. Our
first measurements using a total skin tissue homogenate
prepared in lysis buffer showed that Cn could be measured
in the sample with the activity of 1.9±0.1 nmol per min
per mg protein (n¼4; 95% confidence interval (CI)
1.82–1.98 nmolmin1mg1). After 14 days of culture (in
Fei medium), the keratinocytes derived from the epidermis
of the same skin showed a Cn activity of
11.1±0.9 nmolmin1mg1. After the separation of the
dermis and the epidermis of the skin from four other donors,
an 8.0 higher Cn activity was measured in the epidermis
ORIGINAL ARTICLE
1686 Journal of Investigative Dermatology (2008), Volume 128 & 2008 The Society for Investigative Dermatology
Received 22 May 2007; revised 10 October 2007; accepted 27 November
2007; published online 17 January 2008
1Department of Clinical Chemistry, Leiden University Medical Center,
Leiden, The Netherlands and 2Department of Dermatology, VU University
Medical Center, Amsterdam, The Netherlands
Correspondence: Dr NPM Smit, Department of Clinical Chemistry, L01-036,
Leiden University Medical Center, Albinusdreef 2, Leiden 2333 ZA, The
Netherlands. E-mail: N.Smit@lumc.nl
Abbreviations: Cn, calcineurin; CsA, cyclosporine A; Prl, pimecrolimus;
Trl, tacrolimus
(1.7±0.4 and 14.0±3.2 nmolmin1mg1 in dermis and
epidermis, respectively) (Figure 1).
In cultures of fibroblasts derived from the dermis and
keratinocytes from the epidermis of the same donor, a 40%
lower Cn activity was found in the keratinocytes. Inhibitions
of Cn activity with 124 nM Trl were 74 and 76% in the
fibroblasts and keratinocytes, respectively (see Table 1). For
another donor, a 55% lower activity was found for the
melanocytes compared to the corresponding keratinocytes.
Inhibition with 124 nM Trl was 89 and 75% in the
keratinocyte and melanocyte cultures, respectively (Table 1).
With 831 nM CsA, this was 25 and 49%, respectively. Mean
Cn activity was higher in fibroblasts (13.6±7.0 nmol per min
per mg protein) than it was in keratinocytes (7.2±3.0 nmol
per min per mg protein) (P¼0.018) (Figure 2). A considerable
spread was observed for the Cn activities in the fibroblast and
keratinocyte cultures (95% CI 9.5–17.7 and 4.9–9.5 nmol per
min per mg protein, respectively). Activities in melanocytes
were the lowest (2.7±0.9 nmolmin1mg1). Low Cn acti-
vities were also found for two melanoma cell cultures
(1.7±1.0 and 1.4±0.5 nmolmin1mg1 for An (n¼ 8) and
M14 (n¼ 5), respectively).
Figure 3 shows the inhibition curves for the inhibition of
Cn after a 24-hour incubation with CsA in two different
fibroblast cultures (F0502, F0503). Maximal inhibition of
63% was found in the culture F0503, and for both cultures
similar IC50 (the half maximal inhibitory concentration)
values were found (Table 2). Inhibition curves for Trl and
Prl were measured using the same two cultures. As can be
seen in Table 2, maximum inhibition of Cn was stronger for
Trl than for CsA and Prl, and IC50 values calculated for Trl are
lower than those for CsA and Prl. All three Cn inhibitors were
more effective in the culture F0503 than in F0502.
As can be concluded from these experiments and our
earlier work with CsA (Sellar et al., 2006), maximal
inhibitions are achieved at concentrations of X831 nM CsA,
X124nM Trl, and 123 nM Prl. Numerous inhibition experi-
ments were subsequently performed using the inhibitors at
these higher concentrations. In Figure 4, it can be seen that
maximal reduction of Cn activity is found for Trl in both
fibroblast and keratinocyte cultures. Somewhat milder
inhibition is obtained with both CsA and Prl (CsA, 36 and
33%; Trl, 57 and 55%; and Prl, 43 and 35% inhibition in
fibroblast and keratinocytes, respectively). As described
above, inhibition of Cn activity in melanocytes with 831 nM
CsA and 124nM Trl was only measured once. Both melanoma
cell cultures showed relatively low Cn activity compared to
that of the melanocytes. After 24 hours treatment of the
melanoma cells, reductions in Cn activity were similar for
CsA and Trl (both n¼ 6) (71 and 69%, respectively).
DISCUSSION
Using a Cn enzyme assay, we were able to investigate Cn






















Figure 1. Measurement of calcineurin activity in dermis and epidermis.
Dermis and epidermis were separated by dispase treatment, homogenized,
and lysed, and calcineurin activity was measured. Material was used from
four different donors.
Table 1. Activity and inhibition of Cn in cell cultures




Fibroblasts 12.7 3.3 26
Keratinocytes 7.7 1.9 24
Donor 2
Keratinocytes 8.5 1.0 11
Melanocytes 3.8 1.0 25
Cn, calcineurin; Trl, Tacrolimus.
1Fibroblasts and keratinocytes originating from one donor and keratino-
cytes and melanocytes originating from a second donor. Measurements
were performed in duplicate cultures for donor 1 and single cultures for
donor 2. Incubations were performed for 24 h with 124 nM Trl.
Keratinocytes were grown in Fei medium.























Figure 2. Calcineurin activity measurements in different fibroblast,
keratinocyte, and melanocyte cultures. Cn activity measurements were
performed in lysates of fibroblasts (Fb, n¼ 14), keratinocytes (Kc, n¼ 9), and
melanocytes (Mc, n¼ 3). Significant differences in Cn activity were observed
between fibroblasts and keratinocytes (*P¼ 0.018) and between keratinocytes
and melanocytes (**P¼ 0.030). All keratinocyte cultures were maintained in
Fei medium.
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activity was found in the epidermal part containing keratino-
cytes (Figure 1). Total skin homogenates containing both
dermis and epidermis showed a Cn activity similar to that
found in dermis alone, which may be explained by the much
larger contribution of the dermal part of the skin. In a large
number of cell cultures of fibroblasts, keratinocyte and
melanocyte activities of Cn were measured. On average,
the highest activity was found in the fibroblast cultures
derived from dermis, and keratinocytes from the epidermis
showed about half the activity of that in fibroblasts (Figure 2).
The activities found in epidermis and fibroblasts were in the
same order as those found for peripheral blood mononuclear
cells isolated from blood. Mean activities in melanocytes
were the lowest (o20% of fibroblasts) and were similar to
that in the two melanoma cell cultures. The melanoma cells
were cultured in the same medium as the fibroblasts,
suggesting that the low Cn activities are cell-specific
(for the melanocytic cells) and not dependent on the culture
conditions. The order of activities of Cn in fibroblasts,
keratinocytes, and melanocytes was also observed in the
experiments where cells were grown from the same
donors (Table 1). In monoculture conditions, the dermal
fibroblasts showed the highest Cn activities, whereas this
was not the case for dermis compared to epidermis. This may
be explained by the high content of connective tissue
(containing macromolecules such as collagen, elastin, and
fibronectin) and relatively low amounts of fibroblasts in
dermis compared to the epidermis that contains high
numbers of closely connected layers of keratinocytes. There-
fore, in fibroblast monocultures, the specific Cn activity (per
mg protein) may be expected to be higher than in the in vivo
total dermis. The meaning of this relatively high Cn activity in
fibroblasts remains to be further investigated. Cn activity has
been demonstrated before in fibroblasts derived from lung
tissue and was suggested to play a role in the synthesis of
collagen (Chen et al., 2003). In keratinocytes, Cn activity has
not been measured before, although it has been recognized
that the Cn/NFAT pathway plays an important role in
keratinocyte differentiation and growth regulation (Santini
et al., 2001; Mammucari et al., 2005; Sakaguchi et al., 2005).
In this respect, variations in Cn activity and the inhibitory
capacity of the Cn inhibitors in different individuals or




















–3 –2 –1 0 1 2 3 4 5
F0502
F0503
Figure 3. Effect of cyclosporine A on Cn activity in two different fibroblast
cultures. Inhibition curves of Cn activity were measured for CsA in culture
medium for two different fibroblast cultures (F0502, F0503). The cultures
were incubated for 24 hours with CsA at 0–8,313 nM in duplicate. CsA was
used from Sigma Chem Co.
Table 2. Inhibition of activity with CsA, Trl, and Prl
CsA2 Trl Prl
Culture1 IC50 (nM) 95% CI Inhib. (%) IC50 (nM) 95% CI Inhib. (%) IC50 (nM) 95% CI Inhib. (%)
F0502 2.0 1.3–3.2 60.7 1.3 1.0–1.8 69.0 20.1 5.1–79.2 35.0
F0503 2.7 1.5–5.0 63.1 0.4 0.3–0.7 75.4 6.0 3.0–11.8 48.7
95% CI; 95% confidence interval; Cn, calcineurin; CsA, cyclosporine A; Inhib., percentage maximal inhibition; Prl, pimecrolimus; Trl, Tacrolimus.
1Two different fibroblast cultures F0502 and F0503 were incubated for 24 h with all three inhibitors (CsA, Trl, and Prl). A third culture F0504 was also used
for CsA and showed an IC50 of 3.6 nM and 57.6% maximal inhibition.
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Figure 4. Inhibition of Cn activity by cyclosporine A, tacrolimus, and
pimecrolimus. Fibroblast (Fb,K) and keratinocyte (Kc, E) cultures were
incubated for 24 hours with CsA (831 or 4,156 nM), Trl (124 or 622 nM), and
Prl (123, 617, 1,235, or 6,173 nM). Inhibition of Cn is shown as the mean
percentage inhibition. Error bars represent SEM for fibroblasts treated with
CsA (n¼ 5), Trl (n¼11), Prl (n¼11), and for keratinocytes (n¼ 5, 9, and 4,
respectively). A total of seven different fibroblast and seven different
keratinocyte cultures were used for the experiments. Inhibition by Trl was
stronger than by CsA and Prl (*P¼ 0.0028, **P¼ 0.0114). CsA was used from
Novartis. Keratinocytes were maintained in either Fei medium or defined
keratinocyte medium (Spiekstra et al., 2005) (see Materials and Methods).
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patients may be of great value to predict the efficacy of
treatment. For Cn, a considerable spread in activities was
found in both keratinocyte and fibroblast cultures. Also, for
the inhibition curves of Cn activities, some difference in IC50
values and maximal inhibitions were found for two fibroblast
cultures (Table 2). Strongest inhibition was found for Trl in
these cultures (with lowest IC50 values and lowest remaining
activities). In another larger set of experiments, variation in
Cn inhibition was also observed in a group of different
fibroblast and keratinocyte cultures (Figure 4). 95% CIs
for the inhibition of Cn activity in both fibroblasts
and keratinocytes combined were 28.5–41.1% for CsA,
47.2–65.7% for Trl, and 33.6–47.8% for Prl. The inhibition
of Cn in these experiments was relatively low, especially for
CsA as compared to the maximal Cn inhibitions calculated
for CsA from the inhibition curves (Table 2). This might be a
consequence of the use of two different preparations of CsA
(Sigma Chem Co., Bornem, Belgium and Novartis, Basel,
Switzerland, respectively) used in the experiments, although
no difference in CsA concentrations for either source was
found. In contrast, the inhibition with CsA in Table 2 could be
dependent on the fibroblast cultures used and their status of
differentiation (during culture). In this respect, we did not
observe clear differences in Cn activities between differen-
tiated keratinocytes cultured with different media (as in
Materials and Methods) or with a keratinocyte-defined,
serum-free medium (KD-SFM; Invitrogen Ltd, Paisley, UK),
resulting in much less differentiated cultures (data not shown).
However, further studies will be required to clarify regulation
of Cn activity during the various growth phases in culture.
Inhibition by the Cn inhibitors as measured in the different
cell types seems to be relevant for clinical practice. For
example, the concentrations of CsA in epidermis after oral
administration of the drug has been reported to vary between
0.8 and 2.5mM (Fisher et al., 1988; Taieb, 2005). This is about
1,000 higher than the IC50 values for CsA that we measured
(Table 2). The IC50 values obtained for CsA, Trl, and Prl in
fibroblasts are relatively low compared to our earlier data
obtained after incubations with fresh blood (Sellar et al.,
2006). Differences in efficiency of Cn inhibition have been
described before for incubation in whole blood and in culture
media (Batiuk et al., 1996). Also incubation times with the
inhibitors for 1 hour, as in our previous experiments (Sellar
et al., 2006), and 24hours in this study will be of influence.
Nevertheless, differences in efficiency of the inhibitors can be
measured confirming strong potency of Trl as a Cn inhibitor.
Using more functional assays, Trl has also been shown to be
more potent than Prl (Grassberger et al., 1999). The strong Cn
inhibition by Trl is in agreement with the lower doses that are
used for treatment of transplant patients in comparison to CsA
and the lower concentrations used topically (0.1 and 0.03%)
in creams, compared to the 1% used for Prl.
Our study shows that keratinocytes and fibroblasts may be
direct targets for Cn inhibition, and functional consequences
need to be further clarified. Interindividual variation in Cn
activities and monitoring responses to Cn inhibition may be
helpful to improve treatment of skin diseases such as
psoriasis, atopic eczema, and vitiligo.
MATERIALS AND METHODS
Skin preparation and cell cultures
Foreskin was obtained from surgery after circumcision and main-
tained in PBS. Subcutaneous fat was removed with scissors. Total
skin tissue was homogenized in a dismembrator after freezing in
liquid nitrogen. The same procedure was used for dermis and
epidermis after separation by overnight treatment with dispase
(grade II; Roche Diagnostics, Mannheim, Germany) at 4 1C. Part of
the samples was used for culture of dermal fibroblasts and epidermal
keratinocytes and melanocytes.
Melanocytes were routinely cultured in Ham’s F10 medium
(Invitrogen Ltd) with 2% fetal calf serum (Hyclone, Logan, UT), 1%
Ultroser-G (Pall Biosepra SA, Cergy, France), 2 ngml1 basic
fibroblast growth factor (PeproTech, Rocky Hill, NJ), 2 ngml1
endothelin-1 (Sigma Chem Co.), 16 nM TPA (12-O-tetradecanoyl-
phorbol-13-acetate; Sigma), and 0.1mM IBMX (3-isobutyl-1-methyl-
xanthine) (Sigma Chem Co.) (Fei medium). Presence of TPA causes
preferential attachment of melanocytes. Melanocytes were selec-
tively detached with trypsin/EDTA (1:8; Invitrogen Ltd) and are thus
separated from any remaining keratinocytes after the first passage.
Contaminating keratinocytes or fibroblasts at later passage of
melanocytes were removed by geneticin treatment (Halaban and
Alfano, 1984; Smit et al., 1995). Epidermal keratinocytes were also
grown in the melanocyte medium without TPA (Fei medium) during
the first three passages only. In other experiments (as indicated), a
defined keratinocyte medium (DMEM/Ham’s F12 medium (3:1),
containing Ultroser-G, insulin, isoproterenol, hydrocortisone, and
penicillin/streptomycin) was used according to concentrations and
suppliers mentioned, as described earlier (Spiekstra et al., 2005).
Fibroblasts and melanoma cells (UCLA-SO-M14 and MM-AN)
were cultured in DMEM (Invitrogen Ltd) with 2.5% fetal calf serum
(Hyclone) and penicillin/streptomycin (Invitrogen Ltd).
All surgery materials were obtained with informed consent. The
Declaration of Helsinki Principles was followed and experimental
procedures were approved by the Leiden University Medical Center
and the VU University Medical Center.
Calcineurin activity measurements
Homogenized tissues (as above) and harvested cell pellets were lysed
in the standard lysis buffer from the Biomol Green Cellular Calcineurin
Assay Kit supplemented with 50mg l1 phenylmethanesulfonylfluor-
ide, 50mg l1 soybean trypsin inhibitor, 5mg l1 leupeptin, 5mg l1
aprotinin, and 5.0mM ascorbic acid. Lysis was performed by three
freeze-thaw cycles (liquid N2/30 1C) followed by removal of the cell
debris by centrifugation (10,000g, 10minutes 4 1C) (Sellar et al.,
2006). Briefly, the Cn protein phosphatase 2B activity was measured
by inhibiting other protein phosphatases with excess okadaic acid. Cn
activity was defined as the calcium-dependent protein phosphatase 2B
by measuring phosphate production in the assay in the presence and
absence of EGTA (ethylene glycol-bis(b-aminoethyl ether)-N,N,N0,N0-
tetraacetic acid) (Sellar et al., 2006). For maximal performance of this
Cn assay, the protein concentration of the samples was standardized
to 0.1–0.2mgml1.
Protein concentration was determined using the Pierce Coomas-
sie Plus Total Protein Assay (PerBio Science, Aalst, Belgium) based
on the method of Bradford (Bradford, 1976).
Inhibition measurements were performed with CsA (was used
either from Novartis (SandImmune) or from Sigma Chem Co. as
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indicated for different experiments), Trl (Sigma Chem Co.), and Prl
(Novartis). Concentration ranges used were 0–8,313 nM CsA,
0–622 nM Trl, and 0–6,173 nM Prl. These concentrations were partly
based on earlier experience, and concentrations of CsA and Trl were
controlled by routine immunoassay methods (Sellar et al., 2006).
Statistics
All data are presented as mean±SD unless otherwise indicated.
Inhibition curves and IC50 values were fitted and analyzed by
sigmoidal dose–response curves using Graphpad Prism software (San
Diego, CA). For the purpose of curve fitting, control (0) values were set
to 2 (0.01nM) (no difference was found for settings of 3 and 4).
Student’s t-test was used for comparison of data to test significance of
difference, which was defined by P-value o0.05.
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